CLINICAL ROLE -
Video
Author(s):
Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.
Ruxolitinib Discontinuation at Conditioning Does Not Increase GVHD Risk in Myelofibrosis
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
GPRC5D-Targeted CAR T-Cell Therapy Shows Promise After BCMA Treatment Failure
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Updates in the Management of Transplant-Ineligible Patients With Multiple Myeloma
From Mutation to Management: Risk Stratification, the Power of JAK Inhibition, and the Pharmacist’s Role